StreetInsider.com News Articles

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September:

Wells Fargo 21^st Annual Healthcare Conference
Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m. ET in Boston, MA

2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. ET in New York, NY

Morgan Stanley 24th Annual Global

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September:

Wells Fargo 21^st Annual Healthcare Conference
Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m. ET in Boston, MA

2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. ET in New York, NY

Morgan Stanley 24th Annual Global

Axsome begins Phase 3 trial of AXS-05 for smoking cessation

Mon, 31 Aug 2026 07:00:11 -0400

Axsome Therapeutics (NASDAQ: AXSM) announced that the first patient has been dosed in the SUMMIT Phase 3 trial evaluating AXS-05 as a smoking cessation treatment in adults, according to a press release.

The SUMMIT trial — an acronym for Studying NMDA and Sigma-1 in Smoking Cessation Treatment — is a randomized, double-blind, active- and placebo-controlled, multicenter study. Participants will be assigned in a 1:1:1 ratio to receive AXS-05, bupropion, or placebo for approximately 12 weeks. The primary endpoint is smoking abstinence at the end of the treatment period.

AXS-05, known chemically as dextromethorphan-bupropion, is an oral investigational drug that acts as an

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Mon, 31 Aug 2026 07:00:00 -0400

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation.

SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults. Active smokers will be randomized in a 1:1:1 ratio to receive

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Mon, 31 Aug 2026 07:00:00 -0400

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation.

SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults. Active smokers will be randomized in a 1:1:1 ratio to receive

H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Mon, 24 Aug 2026 06:45:49 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $290.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
The analyst commented: "Axsome Therapeutics recently reported its 2Q26 financial results, recording total revenue of $218.4M in the period. This modestly exceeded our forecast of $211.1M. Our full-year 2026 revenue forecast has risen slightly to $874.6M from the prior $867.6M, while our full-year 2027 revenue forecast remains essentially unchanged at $1.571B. The company recorded a 2Q26 net loss of $0.99 per share, in-line with our estimate. We currently expect a full-year 2026 net loss of $4.10 per share vs. the prior estimate for

Axsome Therapeutics (AXSM) PT Raised to $316 at Mizuho

Wed, 12 Aug 2026 06:38:21 -0400
(Updated - August 12, 2026 6:38 AM EDT)
Mizuho analyst Graig Suvannavejh raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $316.00 (from $306.00) while maintaining a Outperform rating.
The analyst commented: "AXSM reported 2Q26 results this week (LINK), with the recent launch of Auvelity in Alzheimer's disease agitation/ADA being the primary focus. With only eight weeks of the launch to comment on, AXSM shared little, but our sense is that management is pleased with results seen thus far and is content to wait for more data before making any other declarative statements. With early signs of the ADA launch suggesting

Axsome Therapeutics (AXSM) PT Raised to $316 at Mizuho

Wed, 12 Aug 2026 06:38:21 -0400
(Updated - August 12, 2026 6:38 AM EDT)
Mizuho analyst Graig Suvannavejh raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $316.00 (from $306.00) while maintaining a Outperform rating.
The analyst commented: "AXSM reported 2Q26 results this week (LINK), with the recent launch of Auvelity in Alzheimer's disease agitation/ADA being the primary focus. With only eight weeks of the launch to comment on, AXSM shared little, but our sense is that management is pleased with results seen thus far and is content to wait for more data before making any other declarative statements. With early signs of the ADA launch suggesting

Axsome Therapeutics (AXSM) PT Lowered to $279 at RBC Capital

Tue, 11 Aug 2026 10:01:53 -0400
(Updated - August 11, 2026 10:01 AM EDT)
RBC Capital analyst Leonid Timashev lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $279.00 (from $304.00) while maintaining an Outperform rating.
The analyst commented: "We Think ADA Launch Is On Track, Underappreciated Catalysts Could Be Incremental Sweeteners; Today AXSM reported their 2Q26 earnings and we had a chance to catch up with mgmt. We saw continued strength from Auvelity as the co executes upon the drug's launch into ADA, and early metrics on patient adds, new prescribe growth, and sampling enthusiasm suggest that the indication can be a meaningful contributor to 2H26

Axsome Therapeutics (AXSM) PT Lowered to $279 at RBC Capital

Tue, 11 Aug 2026 10:01:53 -0400
(Updated - August 11, 2026 10:01 AM EDT)
RBC Capital analyst Leonid Timashev lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $279.00 (from $304.00) while maintaining an Outperform rating.
The analyst commented: "We Think ADA Launch Is On Track, Underappreciated Catalysts Could Be Incremental Sweeteners; Today AXSM reported their 2Q26 earnings and we had a chance to catch up with mgmt. We saw continued strength from Auvelity as the co executes upon the drug's launch into ADA, and early metrics on patient adds, new prescribe growth, and sampling enthusiasm suggest that the indication can be a meaningful contributor to 2H26

Axsome Therapeutics (AXSM) PT Raised to $251 at Morgan Stanley

Tue, 11 Aug 2026 09:08:31 -0400
Morgan Stanley analyst Sean Laaman raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $251.00 (from $242.00) while maintaining a Equalweight rating.

Axsome Therapeutics (AXSM) PT Raised to $268 at Needham

Tue, 11 Aug 2026 07:11:56 -0400
(Updated - August 11, 2026 7:11 AM EDT)
Needham analyst Ami Fadia raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $268.00 (from $267.00) while maintaining a Buy rating.
The analyst commented: "AXSM traded up ~4% following the 2Q earnings report, with Auvelity continuing to grow nicely in MDD benefiting from the sales force expansion in 2Q and improved coverage. Early launch metrics for the ADA indication were encouraging (+26% QoQ NBRx +12% QoQ TRx, +126% in >65 yr old pts Y/Y in 1st 8 wks of launch) with positive HCP feedback and strong demand for samples in the community setting.

Axsome Therapeutics (AXSM) PT Raised to $268 at Needham

Tue, 11 Aug 2026 07:11:56 -0400
(Updated - August 11, 2026 7:11 AM EDT)
Needham analyst Ami Fadia raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $268.00 (from $267.00) while maintaining a Buy rating.
The analyst commented: "AXSM traded up ~4% following the 2Q earnings report, with Auvelity continuing to grow nicely in MDD benefiting from the sales force expansion in 2Q and improved coverage. Early launch metrics for the ADA indication were encouraging (+26% QoQ NBRx +12% QoQ TRx, +126% in >65 yr old pts Y/Y in 1st 8 wks of launch) with positive HCP feedback and strong demand for samples in the community setting.

Axsome Therapeutics (AXSM) PT Raised to $275 at Guggenheim

Tue, 11 Aug 2026 06:57:01 -0400
(Updated - August 11, 2026 6:57 AM EDT)
Guggenheim analyst Yatin Suneja raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $275.00 (from $260.00) while maintaining a Buy rating.
The analyst commented: "Takeaways from the 2Q26 earnings release include: (1) Auvelity sales came in at $180.3MM for 2Q26 (above consensus), with ~266k TRx, as robust demand continues to drive growth; the sales force expansion to ~630 reps was completed in the quarter and the ADA launch kicked off in June 2026, with early NBRx among patients ≥65 up 126% in the first eight weeks; (2) Sunosi continues to perform well ($35.8MM

Axsome Therapeutics (AXSM) PT Raised to $275 at Guggenheim

Tue, 11 Aug 2026 06:57:01 -0400
(Updated - August 11, 2026 6:57 AM EDT)
Guggenheim analyst Yatin Suneja raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $275.00 (from $260.00) while maintaining a Buy rating.
The analyst commented: "Takeaways from the 2Q26 earnings release include: (1) Auvelity sales came in at $180.3MM for 2Q26 (above consensus), with ~266k TRx, as robust demand continues to drive growth; the sales force expansion to ~630 reps was completed in the quarter and the ADA launch kicked off in June 2026, with early NBRx among patients ≥65 up 126% in the first eight weeks; (2) Sunosi continues to perform well ($35.8MM

Axsome Therapeutics (AXSM) PT Raised to $256 at Wells Fargo

Tue, 11 Aug 2026 06:54:45 -0400

Wells Fargo analyst Benjamin Burnett raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $256.00 (from $255.00) while maintaining a Overweight rating.
The analyst comments "Uptake of Auvelity in AD Agitation is in its infancy, but mgmt commentary is encouraging. We think 3Q26 and 4Q26 will be more important for setting revenue growth expectations. Meanwhile, mgmt remains focused on achieving cash flow pos. Stock setup. We think there's a lot of focus on the uptake of Auvelity in AD Agitation, though we also think 2Q26 was never viewed as a key indicator of revenue growth. Rather, we think expecations are

Axsome Therapeutics (AXSM) PT Raised to $256 at Wells Fargo

Tue, 11 Aug 2026 06:54:45 -0400

Wells Fargo analyst Benjamin Burnett raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $256.00 (from $255.00) while maintaining a Overweight rating.
The analyst comments "Uptake of Auvelity in AD Agitation is in its infancy, but mgmt commentary is encouraging. We think 3Q26 and 4Q26 will be more important for setting revenue growth expectations. Meanwhile, mgmt remains focused on achieving cash flow pos. Stock setup. We think there's a lot of focus on the uptake of Auvelity in AD Agitation, though we also think 2Q26 was never viewed as a key indicator of revenue growth. Rather, we think expecations are

Form 10-Q Axsome Therapeutics, For: Jun 30

Mon, 10 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260810/26897877.html

Form 10-Q Axsome Therapeutics, For: Jun 30

Mon, 10 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260810/26897877.html

Axsome Therapeutics (AXSM) Misses Q2 EPS by 14c

Mon, 10 Aug 2026 07:39:53 -0400

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($0.99), $0.14 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $218.37 million versus the consensus estimate of $221.92 million.
For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

Form 8-K Axsome Therapeutics, For: Aug 10

Mon, 10 Aug 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20260810/26894167.html

Form 8-K Axsome Therapeutics, For: Aug 10

Mon, 10 Aug 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20260810/26894167.html

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 10 Aug 2026 07:00:00 -0400

Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth

AUVELITY^® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth

SUNOSI^® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth

SYMBRAVO^® 2Q 2026 net product sales of $2.3 million

AUVELITY launched for treatment of agitation associated with dementia due to Alzheimer’s disease in June 2026

NDA submission for AXS-12 for cataplexy in narcolepsy accepted by the FDA with PDUFA target action date of May 1, 2027

FOCUS-2 and

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 10 Aug 2026 07:00:00 -0400

Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth

AUVELITY^® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth

SUNOSI^® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth

SYMBRAVO^® 2Q 2026 net product sales of $2.3 million

AUVELITY launched for treatment of agitation associated with dementia due to Alzheimer’s disease in June 2026

NDA submission for AXS-12 for cataplexy in narcolepsy accepted by the FDA with PDUFA target action date of May 1, 2027

FOCUS-2 and

Form 4 Axsome Therapeutics, For: Aug 05 Filed by: TABUTEAU HERRIOT

Fri, 07 Aug 2026 19:00:00 -0400
si-local-file:///var/storage/secattach/20260807/26892465.html